2.5. Randomized Controlled Trial (RCT) Data to Validate the Effects of Fluticasone on the Expression of Specific Genes
COPD
COPD
One of the top therapeutic hits in IPA was fluticasone. To validate this predicted drug target in vivo, we used data from the DISARM trial, which was a RCT (clinicaltrials.gov NCT02833480) in which patients with COPD were treated for 3 months with (1) inhaled fluticasone (in combination with salmeterol), (2) inhaled budesonide (in combination with formoterol), or (3) inhaled formoterol alone [